Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR +1.63%87 Equity-to-Asset is 0.89 as of Jun. 2026, which is 13% above its 10-year median of 0.79. GuruFocus rates UTHR with a GF Score™ of 87/100 and a GF Value™ of $426.58 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, United Therapeutics ranks better than 92.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. United Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $6,400 Mil. United Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $7,220 Mil.
Therefore, United Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.89.
The historical rank and industry rank for United Therapeutics's Equity-to-Asset or its related term are showing as below:
UTHR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.63 Med: 0.79 Max: 0.91
Current: 0.89
During the past 13 years, the highest Equity to Asset Ratio of United Therapeutics was 0.91. The lowest was 0.63. And the median was 0.79.
UTHR's Equity-to-Asset is ranked better than 92.94% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs UTHR: 0.89
United Therapeutics (NAS:UTHR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
United Therapeutics Equity-to-Asset Related Terms
United Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
United Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a Equity-to-Asset of 0.89 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on United Therapeutics and its competitors. This is 13% above median its historical median of 0.79. Over the past decade, United Therapeutics' Equity-to-Asset has ranged from 0.63 to 0.91. According to the industry distribution chart, United Therapeutics ranks #71 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is United Therapeutics' Equity-to-Asset too high?
United Therapeutics' current Equity-to-Asset of 0.89 is 13% above median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 0.91. The Drug Manufacturers industry median Equity-to-Asset is 0.61. United Therapeutics' value of 0.89 is 45.9% above this industry median. Based on the distribution chart, United Therapeutics ranks #71 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Equity-to-Asset compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #71 out of 1005 companies for Equity-to-Asset. This places United Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. United Therapeutics' value of 0.89 is 45.9% above this benchmark. Historically, United Therapeutics' own Equity-to-Asset has ranged from 0.63 to 0.91 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.61, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Equity-to-Asset of 0.89 is 45.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Equity-to-Asset is 0.89, which is 13% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Modestly Overvalued. The stock's GF Value™ is $426.58, compared to a current price of $507.82 — trading 19% above its estimated fair value. The current Equity-to-Asset is 0.89, which is 13% above median its 10-year median of 0.79 and 45.9% above the Drug Manufacturers industry median of 0.61. United Therapeutics' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Equity-to-Asset is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $507.82 is trading 19% above its estimated GF Value™ of $426.58.
GuruFocus considers United Therapeutics to be Modestly Overvalued.
Key valuation signals for UTHR:
Equity-to-Asset: 0.89 (13% above median its 10-year median of 0.79)
GF Value™: $426.58 vs. price of $507.82 (19% above fair value)
Industry Position: 45.9% above the Drug Manufacturers median (#71 of 1005)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
87GF Score
Get the complete analysis for UTHR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
